Biogazelle, Isis Pharmaceuticals Collaborate on Long Non-Coding RNA Technology | GenomeWeb

NEW YORK (GenomeWeb) – Biogazelle today announced a research collaboration with Isis Pharmaceuticals to identify and validate novel drug targets. 

The collaboration is aimed at treatments for colon, liver, and lung cancer. Isis will provide Biogazelle with access to its antisense platform for the large-scale validation of therapeutic long non-coding RNA targets from Biogazelle's target identification pipeline. 

Financial and other details of the deal were not disclosed. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.